DNLI

Business Context and Reporting Period

Company: Denali Therapeutics Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Denali is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for neurodegenerative and lysosomal storage diseases. The company utilizes its proprietary Transport Vehicle (TV) platform to deliver large molecules across the blood-brain barrier. As of September 30, 2024, the company had no products approved for commercial sale and no product revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Collaboration revenue was $0 for the three and nine months ended September 30, 2024, compared to $1.3 million and $330.5 million in the same periods of 2023. The 2023 revenue was driven by a $293.9 million milestone from Biogen related to the ATV:Abeta program option exercise, which did not recur in 2024.
• Net Loss: Net loss increased to $107.2 million for the quarter (from $99.4 million in Q3 2023) and $308.0 million for the nine-month period (from $25.8 million in 2023). The significant increase in the nine-month loss is primarily due to the absence of the large Biogen milestone revenue recognized in 2023.
• Divestiture Gain: The company recognized a non-cash gain of $14.5 million in the nine months ended September 30, 2024, from the divestiture of preclinical small molecule programs. This gain was not present in the prior year.
• Liquidity: Cash, cash equivalents, and marketable securities totaled $1.28 billion as of September 30, 2024, bolstered by a $499.3 million private placement in February 2024.

Guidance, Outlook, and Management Commentary

• Regulatory Milestones: Management announced plans to file a Biologics License Application (BLA) for accelerated approval of tividenofusp alfa (DNL310) for Hunter syndrome (MPS II) in early 2025, following a successful meeting with the FDA.
• Clinical Updates:
  • ETV:IDS (DNL310): Enrollment in the Phase 2/3 COMPASS study is expected to complete in 2024.
  • ETV:SGSH (DNL126): Preliminary data from the Phase 1/2 study in MPS IIIA showed significant reduction in CSF HS levels; the study has been expanded.
  • LRRK2 (BIIB122/DNL151): A new $75 million funding agreement was entered into for a global Phase 2a study in Parkinson's disease. Screening has begun.
  • Discontinued Programs: Biogen terminated its license to the ATV:Abeta program in July 2024. Sanofi discontinued the K2 Phase 2 study of SAR443820/DNL788 in multiple sclerosis due to not meeting endpoints.
• Capital Resources: Management believes existing cash and marketable securities are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring significant operating losses as it advances clinical programs.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional funding, reliance on third-party manufacturers, and the potential for collaboration terminations.

Investor Verification Checklist

• BLA Filing Timeline: Verify the specific timeline and regulatory feedback for the planned early 2025 BLA submission for DNL310.
• Collaboration Revenue Exposure: Assess the impact of the Biogen ATV:Abeta termination on future revenue streams and the reliance on the LRRK2 program with Biogen.
• Cash Burn Rate: Monitor the quarterly cash burn rate against the $1.28 billion liquidity position to confirm the 12-month runway estimate.
• Divestiture Consideration: Review the status of the $15 million SAFE (Simple Agreement for Future Equity) received from the divestiture of small molecule programs and potential milestone payments.
• Manufacturing Capacity: Evaluate the progress of the internal manufacturing facility build-out in Salt Lake City and reliance on third-party CDMOs.